# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-122067
Filing Date
2022-11-25
Accepted
2022-11-25 14:00:10
Documents
5
Period of Report
2023-01-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2230379-2_def14a.htm | DEF 14A | 243386
2 | GRAPHIC | lg_vyne-4c.jpg | GRAPHIC | 28421
3 | GRAPHIC | sg_daviddomzalskinew01-bw.jpg | GRAPHIC | 7330
4 | GRAPHIC | tm2230379d2-px_01pagebw.jpg | GRAPHIC | 507508
5 | GRAPHIC | tm2230379d2-px_02pagebw.jpg | GRAPHIC | 200933
| Complete submission text file | 0001104659-22-122067.txt |  | 1269691

Mailing Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38356 | Film No.: 221419698
SIC: 2834 Pharmaceutical Preparations